Baseline data
| Patient characteristic | Mean (SD) or n | Normal range |
|---|---|---|
| ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; HMG-CoA, hydroxymethyl glutaryl coenzyme A. | ||
| Age (years) | 60.8 (4.6) | |
| Body mass index (kg/m2) | 31.3 (2.87) | |
| Total testosterone (nmol/l) | 4.2 (0.5) | >7.5 |
| Bioavailable testosterone (nmol/l) | 1.7 (0.4) | >2.5 |
| Follicle stimulating hormone (nmol/l) | 6.6 (3.6) | 1.1–13.3 |
| Luteinising hormone (nmol/l) | 4.5 (3.5) | 1.4–9.2 |
| Prostate specific antigen (μg/l) | 1.01 (1.3) | <5 |
| Angiographically proven coronary disease | 10 | |
| Previous myocardial infarction | 3 | |
| Diabetes mellitus | 5 | |
| Hypertension | 5 | |
| Aspirin | 9 | |
| Clopidogrel | 3 | |
| ACE or ARB | 5 | |
| β Blocker | 9 | |
| Calcium channel antagonist | 9 | |
| Oral nitrate | 8 | |
| HMG-CoA reductase inhibitor | 10 | |
| Previous CABG | 1 | |
| Previous angioplasty | 2 | |